Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial

Journal of Hepatology

Volumn 60, Issue 4, 2014, Pages 699-705

  Shoeb, D ^a   Dearden, J ^a   Weatherall, A ^a   Bargery, C ^a   Moreea, S ^b   Alam, S ^b   White, E ^c   Vila, X ^d   Freshwater, D ^e   Ryder, S ^f   Mills, P R ^g   Alexander, G J ^h   Forton, D ⁱ   Foster, G R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f QUEEN S MEDICAL CENTRE   (United Kingdom)

^g GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cirrhosis; Extended therapy; Genotype 3; HCV; PegIFN RBV; Sustained virologic response

Indexed keywords

INTERLEUKIN 28; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; EPILEPSY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOKALEMIA; INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SEPSIS; SIDE EFFECT; SLEEP DISORDER; SUICIDE ATTEMPT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; PATHOLOGY; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84896395551     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.11.011     Document Type: Article

References (22)

1. B.R. Das, B. Kundu, R. Khandapkar, and S. Sahni Geographical distribution of hepatitis C virus genotypes in India Indian J Pathol Microbiol 45 2002 323 328
2. M. Idrees, and S. Riazuddin Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission BMC Infect Dis 8 2008 69 76
3. M. Stamouli, I. Panagiotou, D. Kairis, A. Michopoulou, A. Skliris, and G. Totos Genotype distribution in chronic hepatitis C patients in Greece Clin Lab 58 2012 173 176
4. M.J. de Vries, B. te Rijdt, and C.M. van Nieuwkerk Genotype distribution amongst hepatitis C patients in The Netherlands Neth J Med 64 2006 109 113
5. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
6. D.A. Freshwater, K. O'Donnell, and D.J. Mutimer Inferior response of Asian vs. non-Asian hepatitis C genotype 3 infection to combination antiviral therapy J Viral Hepat 15 2008 115 119
7. D. Shoeb, I.A. Rowe, D. Freshwater, D. Mutimer, A. Brown, and S. Moreea et al. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse Eur J Gastroenterol Hepatol 23 2011 747 753
8. J.G. McHutchison, G. Dusheiko, M.L. Shiffman, M. Rodriguez-Torres, S. Sigal, and M. Bourliere et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2007 2227 2236
9. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2012 2405 2416
10. G.R. Foster, C. Hézode, J.P. Bronowicki, G. Carosi, O. Weiland, and L. Verlinden et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 e1
11. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2012 1195 1206
12. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
13. A. Mangia, R. Santoro, N. Minerva, G.L. Ricci, V. Carretta, and M. Persico et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2005 2609 2617
14. M.L. Shiffman, F. Suter, B.R. Bacon, D. Nelson, H. Harley, and R. Solá et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124 134
15. T. von Berg, M. Wagner, S. Nasser, C. Sarrazin, T. Heintges, and T. Gerlach et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs. 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 2006 1086 1097
16. Cheinquer H, Shiffman ML, Zeuzem S, Christoph Berg, Thomas Berg, Cláudio de Figueiredo Mendes, et al. The outcome of 24 vs 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. In: Program and abstracts of the 63rd annual meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, November 9-13; 2012 [abstract 156].
17. B. Helbling, W. Jochum, I. Stamenic, M. Knöpfli, A. Cerny, and J. Borovicka et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin J Viral Hepat 13 2006 762 769
18. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
19. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
20. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
21. O. Dalgard, K. Bjøro, H. Ring-Larsen, E. Bjornsson, M. Holberg-Petersen, and E. Skovlund et al. Pegylated interferon alfa and ribavirin for 14 vs. 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response Hepatology 47 2008 35 42
22. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, and A.M. Sheikh et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408